Pharmalex SRL
15.0 FTEThe score of Pharmalex shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +1 % Total assets -4 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharmalex's annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 08 Jan 2026
- Year ended 30 Jun 2024filed on 19 Dec 2024
- Year ended 30 Jun 2023filed on 25 Jan 2024
- Year ended 30 Jun 2022filed on 23 Dec 2022
- Year ended 31 Dec 2021filed on 28 Mar 2022
Pharmalex's financial analysis
- Solvency84.3%sector median: 48.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharmalex
Pharmalex's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0471.925.883
- VAT number
- BE0471925883
- Peppol
- Registered · 0208:0471925883 · as of 01 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 May 2000
- Registered office
- 4020 Liège
- Size
- Small · 15.0 FTE
- Latest accounts
- 2025 · filed on 08 Jan 2026
- Activity
- Activities of certified accountants (tax experts) (NACE 69201)
Pharmalex (SRL) has been based in Liège since 2000, active in: activities of certified accountants (tax experts). For 2025, it reports a net profit of 64,882 € and equity of €1.92m; its revenue is not published. With 15.0 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 84.3%, above the median of its sector (48.1%).
Companies similar to Pharmalex
Companies in the same business, of comparable size and area, outside its group.
- Cabinet D'Expertise Comptable Dejon Accounting, bookkeeping and auditing activities; tax consultancy Saint-Georges-sur-Meuse · balance sheet €2.17m
- Accountancy Kava Accounting, bookkeeping and auditing activities; tax consultancy Antwerp · balance sheet €2.27m
- Hugues Lamon Accounting, bookkeeping and auditing activities; tax consultancy Uccle · balance sheet €2.28m
- Fiscopolis Accounting, bookkeeping and auditing activities; tax consultancy Nazareth-De Pinte · balance sheet €2.28m
- Online Tax Accounting, bookkeeping and auditing activities; tax consultancy Ghent · balance sheet €2.26m
- Boekhoudkantoor Doolaeghe Accounting, bookkeeping and auditing activities; tax consultancy Kortrijk · balance sheet €2.29m
- ACF Group Accounting, bookkeeping and auditing activities; tax consultancy Châtelet · balance sheet €2.29m
- Goezicht Accounting, bookkeeping and auditing activities; tax consultancy Lo-Reninge · balance sheet €2.29m
Frequently asked questions about Pharmalex
What is the revenue of Pharmalex?
Pharmalex files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharmalex?
In Belgium, the VAT number is the company number prefixed with BE: BE0471925883 for Pharmalex, if the company is VAT-registered. Its company number (CBE) is 0471.925.883.
Where is the registered office of Pharmalex?
According to the CBE register, the registered office of Pharmalex is in 4020 Liège.
What is the equity of Pharmalex?
At the close of the 2025 financial year, the equity of Pharmalex amounts to 1,916,472 €, a solvency of 84.3% of total assets.
How many people work at Pharmalex?
15.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Pharmalex?
The register lists 2 active mandates at Pharmalex. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharmalex
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →